$3.35
3.08% yesterday
Nasdaq, Aug 12, 10:18 pm CET
ISIN
US75943R1023
Symbol
RLAY

Relay Therapeutics Inc Stock price

$3.35
-0.21 5.90% 1M
-0.41 10.90% 6M
-0.77 18.69% YTD
-3.16 48.54% 1Y
-17.35 83.82% 3Y
-35.53 91.38% 5Y
-31.70 90.44% 10Y
-31.70 90.44% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.10 3.08%
ISIN
US75943R1023
Symbol
RLAY
Industry

Key metrics

Basic
Market capitalization
$560.3m
Enterprise Value
$-150.0m
Net debt
positive
Cash
$710.4m
Shares outstanding
170.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
73.0 | 47.6
EV/Sales
negative | negative
EV/FCF
0.6
P/B
0.8
Financial Health
Equity Ratio
89.3%
Return on Equity
-43.4%
ROCE
-48.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.7m | $11.8m
EBITDA
$-361.7m | $-361.1m
EBIT
$-367.0m | $-358.0m
Net Income
$-333.4m | $-324.8m
Free Cash Flow
$-272.6m
Growth (TTM | estimate)
Revenue
-87.4% | 17.6%
EBITDA
43.3% | 1.6%
EBIT
42.9% | 3.9%
Net Income
43.3% | 3.8%
Free Cash Flow
5.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,710.2% | -3,068.9%
EBIT
-4,778.9%
Net
-4,341.5% | -2,760.2%
Free Cash Flow
-3,550.2%
More
EPS
$-2.0
FCF per Share
$-1.6
Short interest
15.2%
Employees
261
Rev per Employee
$40.0k
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Relay Therapeutics Inc forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Relay Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.68 7.68
87% 87%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 76 76
43% 43%
983%
- Research and Development Expense 320 320
45% 45%
4,165%
-362 -362
43% 43%
-4,710%
- Depreciation and Amortization 5.28 5.28
3% 3%
69%
EBIT (Operating Income) EBIT -367 -367
43% 43%
-4,778%
Net Profit -333 -333
43% 43%
-4,341%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Neutral
The Motley Fool
5 days ago
Relay (RLAY) Q2 Loss Narrows 41%
Neutral
GlobeNewsWire
5 days ago
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash, cash equivalents and investments at end of Q2 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RL...
Positive
Seeking Alpha
11 days ago
Upgraded Relay Therapeutics to a buy after an unjustified valuation decline, maintaining cautious optimism. Recent ASCO data and quarterly updates provide new insights into the evolving investment thesis for RLAY. Pipeline progress and financial health remain central to the company's long-term value proposition and risk profile.
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 261
Founded 2015
Website relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today